Last reviewed · How we verify

NCT02749409

Early Parecoxib Usage to Decreases Narcotic Requirement and Length of Stay After Traumatic Rib Fracture

Terminated Phase 3 Last updated 31 January 2020
What this trial tests

Phase 3 trial testing Parecoxib in Parecoxib in 17 participants. Terminated before completion.

Timeline
8 August 2016
Primary endpoint
10 July 2018
20 July 2018

Quick facts

Lead sponsorChang Gung Memorial Hospital
PhasePhase 3
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment17
Start date8 August 2016
Primary completion10 July 2018
Estimated completion20 July 2018

Drugs / interventions tested

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

18 and older, any sex, with Parecoxib or Rib Fractures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients diagnosed traumatic rib fracture and need admission will be included. Patients will be divided two groups.The experimental group will be given parecoxib after visiting emergency department. The control group will be given Narcotic agent such as morphine for pain control. The outcome such as numerical rating scale (NRS) and hospital length of stay will be recorded.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Parecoxib

Trials testing the same drug.

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02749409.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing